Document Detail

Evidence-based, multidisciplinary approach to the development of a crotalidae polyvalent antivenin (CroFab) protocol at a university hospital.
MedLine Citation:
PMID:  20124465     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Several thousand people are bitten annually by venomous snakes in the US. While the development of ovine Crotalidae polyvalent immune Fab antivenin (FabAV) for Crotalinae snakebite envenomations has greatly changed the way this clinical presentation is treated, multiple issues complicate its use. From patient assessment and evaluation, to medication preparation and administration, to the management of adverse drug reactions, the use of this antidote carries with it multiple points of possible medication variances. The inappropriate use of this agent can result in adverse patient consequences and a significant financial burden for both the hospital and the patient. OBJECTIVE: To describe an evidence-based, multidisciplinary approach that was taken to ensure optimal, safe, and cost-effective treatment of patients with FabAV. METHODS: Following an analysis of the available literature, a multidisciplinary committee was formed to construct a protocol for use of FabAV. This group included clinical pharmacists, pharmacy administrators, emergency medicine physicians who specialized in wilderness medicine and pharmacy residents. RESULTS: A multidisciplinary FabAV usage protocol was constructed and implemented to ensure appropriate patient evaluation, FabAV use and preparation, monitoring, and follow-up. This protocol was based on the available literature and the expert opinion of the committee. Through the use of a 24-hour in-house pharmacy resident on-call system, clinical pharmacy services were provided to ensure a multidisciplinary approach to the care of these patients emergently. Although limited, initial data show that this approach is effective and may result in substantial cost savings. CONCLUSIONS: Initial results from implementation of a protocol for use of FabAV have limited inappropriate use, reduced medication wastage, and decreased costs.
Kyle A Weant; Peter N Johnson; Rebecca C Bowers; John A Armitstead
Related Documents :
24903795 - Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug res...
16307705 - A markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of gl...
23647445 - Randomized, open-label study to evaluate patient-reported outcomes with fingolimod afte...
22919335 - Factors predicting ventilator dependence in patients with ventilator-associated pneumonia.
20308885 - Long-term mortality and quality of life in sepsis: a systematic review.
8035395 - Acth revisited: effective treatment for acute crystal induced synovitis in patients wit...
Publication Detail:
Type:  Journal Article     Date:  2010-02-02
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  44     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-04     Completed Date:  2010-05-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  447-55     Citation Subset:  IM    
Department of Pharmacy Services, University of Kentucky HealthCare, Lexington, KY 40536, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antivenins / administration & dosage*,  economics
Clinical Protocols
Cost-Benefit Analysis
Crotalid Venoms / antagonists & inhibitors
Evidence-Based Medicine / methods*
Hospitals, University
Immunoglobulin Fragments / administration & dosage*,  economics
Pharmacy Service, Hospital / organization & administration
Snake Bites / therapy
United States
Reg. No./Substance:
0/Antivenins; 0/Crotalid Venoms; 0/Crotalidae Polyvalent immune Fab; 0/Immunoglobulin Fragments

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist (March) (CE).
Next Document:  Effectiveness and Safety of Proton Pump Inhibitors in Infantile Gastroesophageal Reflux Disease (Mar...